FDA and EMA waive paediatric studies for Shanton’s gout candidate
SAP-001 will not require paediatric studies in market authorisation applications for hyperuricemia and gout.
Drug Development
Litmys and PharmaACE partner on pharma commercial forecasting
ProBio signs global antibody licensing deal with AbTis
Lilly-backed Oyster Therapeutics raises $60m for neurological degraders
Delix Therapeutics raises $100m for zalsupindole development
Charles River agrees $470m deal for Frontage assets
Network Bio partners with Duke University on AI disease models
Bio-Thera gains Chinese approval for spondylitis and rheumatoid arthritis drug
